Format

Send to

Choose Destination
Cancer. 2019 Mar 5. doi: 10.1002/cncr.32004. [Epub ahead of print]

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Author information

1
University of Texas MD Anderson Cancer Center, Houston, Texas.
2
Dana-Farber Cancer Institute, Boston, Massachusetts.
3
University of Oxford, Oxford, United Kingdom.
4
Roswell Park Cancer Institute, Buffalo, New York.
5
Barts Cancer Institute, London, United Kingdom.
6
NYU Langone Medical Center, New York, New York.
7
Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
8
University of Cambridge, Cambridge, United Kingdom.
9
Harvard Medical School, Boston, Massachusetts.
10
University of Pennsylvania, Philadelphia, Pennsylvania.
11
University of Chicago, Chicago, Illinois.
12
University of Pittsburgh, Pittsburgh, Pennsylvania.
13
Brigham and Women's Hospital, Boston, Massachusetts.
14
University of Glasgow, Glasgow, United Kingdom.
15
University of British Columbia, Vancouver, British Columbia, Canada.
16
CTEP NCI, Rockville, Maryland.
17
Institute of Cancer Research, London, United Kingdom.
18
BC Cancer Agency, Vancouver, British Columbia, Canada.
19
University of Toronto, Toronto, Ontario, Canada.
20
Johns Hopkins University School of Medicine, Baltimore, Maryland.
21
Massachusetts General Hospital, Boston, Massachusetts.
22
University of Helsinki, Helsinki, Finland.
23
The Wistar Institute, Philadelphia, Pennsylvania.

Abstract

Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on "Critical Questions in Ovarian Cancer Research and Treatment" was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

KEYWORDS:

PARP inhibitors; drug resistance; early detection; heterogeneity; immunotherapy; metabolism; microenvironment; ovarian cancer; prevention

PMID:
30835824
DOI:
10.1002/cncr.32004

Supplemental Content

Full text links

Icon for Wiley Icon for NYU School of Medicine
Loading ...
Support Center